期刊
GENOME RESEARCH
卷 22, 期 11, 页码 2101-2108出版社
COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
DOI: 10.1101/gr.131128.111
关键词
-
资金
- Enzon
- Xcovery
- AstraZeneca
- Symphogen
- VICC Specialized Program of Research Excellence in Lung Cancer grant [CA90949]
- Vanderbilt-Ingram Cancer Center [CA68485]
- V Foundation
- TJ Martell Foundation
- Robert J. Kleberg Jr. and Helen C. Kleberg Foundation
We are currently in an era of rapidly expanding knowledge about the genetic landscape and architectural blueprints of various cancers. These discoveries have led to a new taxonomy of malignant diseases based upon clinically relevant molecular alterations in addition to histology or tissue of origin. The new molecularly based classification holds the promise of rational rather than empiric approaches for the treatment of cancer patients. However, the accelerated pace of discovery and the expanding number of targeted anti-cancer therapies present a significant challenge for healthcare practitioners to remain informed and up-to-date on how to apply cutting-edge discoveries into daily clinical practice. In this Perspective, we use lung cancer as a paradigm to discuss challenges related to translating genomic information into the clinic, and we present one approach we took at Vanderbilt-Ingram Cancer Center to address these challenges.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据